Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte

INDIANAPOLIS, Oct. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT®) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020....

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eli Lilly To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 29, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE:LLY).If you suffered losses exceeding $100,000 investing in Eli Lilly stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/LLY or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330...

Eli Lilly Investor Alert

Eli Lilly's (LLY) progress in antibodies treatment is expected to raise investors' optimism.

ETFs to Shine on Lilly's U.S. Deal for Coronavirus Antibody

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today announced that it has raised $40.5 million of cash via:

Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors

INDIANAPOLIS, Oct. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz® (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with psoriasis and psoriatic arthritis. Notably, Lilly will...

New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis

Shares of Eli Lilly & Co. were up 0.8% in after-hours trading on Wednesday after an analysis published in theNew England Journal of Medicine found that the drug maker's experimental antibody treatment led to fewer hospitalizations and "symptom burden" compared with those COVID-19 patients who had received a placebo. Earlier on Wednesday Lilly announced a deal with the U.S. government to acquire 300,000 doses of the still-unauthorized treatment for $375 million.

Study: Lilly's experimental COVID-19 drug may reduce hospitalizations

INDIANAPOLIS, Oct. 28, 2020 /PRNewswire/ -- The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the...

Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine

The US government has agreed to pay $375 million to Eli Lilly for 300,000 doses of its experimental COVID-19 antibody treatment, a drug similar to a treatment that President Trump received. Lilly will start delivering the doses within two months of receiving an emergency use authorization from the Food and Drug Administration, the company said.

US strikes $375M deal with Eli Lilly for potential COVID-19 drug

Eli Lilly said the government has agreed that patients will pay no out-of-pocket costs.

Eli Lilly Announces Deal With U.S. Government To Supply Its Coronavirus Antibody Treatment

Extra Space Storage

Freeport-McMoRan

Alphabet

Jazz Pharmaceuticals

Medtronic

Parker-Hannifin

Royal Caribbean Cruises

Waters

Walmart

It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.

BofA Securities Top 10 US Stock Ideas for the Rest of 2021

Eli Lilly inked a deal to sell up to 650,000 vials of its Covid-19 treatment candidate to the U.S., though the drug has failed a test in treating hospitalized patients. LLY stock slipped.

Eli Lilly Inks Covid-19 Treatment Supply Deal With U.S. Despite Drug's Recent Failure

The agreement is for delivery over the two months following an emergency use authorization from the Food and Drug Administration.

U.S. agrees to pay Eli Lilly $375 million for 300,000 doses of coronavirus antibody drug

INDIANAPOLIS, Oct. 28, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will...

Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19

One clinical trial failure isn't the end of Eli Lilly's COVID-19 response.

What's Next for Eli Lilly's COVID-19 Antibodies?

Shares of Eli Lilly & Co. were down 0.7% in premarket trading on Wednesday after the drug maker said the U.S. government signed a deal to acquire 300,000 doses of its experimental neutralizing antibody COVID-19 treatment bamlanivimab for $375 million. Per the terms of the deal, Lilly will distribute vials of the drug, which is also referred to as LY-CoV555, to the government if the Food and Drug Administration grants an emergency use authorization.

Lilly signs deal with U.S. government for still-investigational COVID-19 antibody drug

Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer

Raytheon Technologies

Find out which two companies set a downbeat tone on Wall Street.

These 2 Big Earnings Reports Led Stock Markets Lower Tuesday

Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2020 Results - Earnings Call Transcript

Eli Lilly And Co's (NYSE: LLY) third-quarter results show the persisting impact of COVID-19 and pricing headwinds, according to BofA Securities. The Eli Lilly Analyst: Geoff Meacham maintained a Buy rating on Eli Lilly with a $180 price target.

BofA On Eli Lilly: Disappointing Q3 Comes In Otherwise Strong 2020

Eli Lilly & Co. (NYSE: LLY) said on Tuesday that its earnings in the fiscal third quarter came in lower than expected. Eli Lilly is one of the prominent names that is committed to developing an effective treatment for COVID-19.

Eli Lilly's net income contracts to £920 million in the fiscal third quarter

Eli Lilly And Co (NYSE: LLY) CEO Dave Ricks was interviewed on “Bloomberg Surveillance” Tuesday morning to offer additional commentary on the company's earlier earnings report and the pharmaceutical giant's outlook. COVID-19 treatment update Eli Lilly has been working on treatments against the COVID-19 virus that consists of a neutralizing antibody meant for symptomatic individuals in an outpatient setting.

Highlights from Eli Lilly CEO's Bloomberg interview

The company's third-quarter financial results did not impress investors.

Why Eli Lilly Stock Is Down Today

Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.

Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down

A major US drugmaker is ending trials for a coronavirus treatment for failing among hospitalized patients.  Eli Lilly announced Monday it would stop a study testing bamlanivimab in hospitalized patients after National Institutes of Health trial data suggested the drug was "unlikely" to help this group recover from the disease. 

Eli Lilly has ended a major COVID-19 antibody test among hospitalized patients (LLY)

Eli Lilly and Company's (LLY) CEO David Ricks on Q3 2020 Results - Earnings Call Transcript

News for Eli Lilly Stock (LLY)